FLT3 Inhibitor III is primarily used in research focused on acute myeloid leukemia (AML) and other hematologic malignancies. It targets the FLT3 receptor tyrosine kinase, which is often mutated in AML, leading to uncontrolled cell proliferation. By inhibiting FLT3, this compound helps to study the mechanisms of leukemia cell growth and survival, providing insights into potential therapeutic strategies. It is also utilized in preclinical studies to evaluate the efficacy of FLT3 inhibition in reducing tumor burden and improving survival in animal models. Additionally, it aids in understanding resistance mechanisms to FLT3 inhibitors, which is crucial for developing more effective treatments for patients with FLT3-mutated cancers.